Quest Diagnostics Gestion
Gestion contrôle des critères 4/4
Le PDG Quest Diagnostics est Jim Davis, nommé en Nov2022, a un mandat de 3.5 ans. La rémunération annuelle totale est $ 15.50M, composée du salaire de 8.1% et des bonus 91.9%, y compris les actions et options de la société. détient directement 0.13% des actions de la société, d'une valeur de $ 27.44M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 3.8 ans et 6.2 ans.
Informations clés
Jim Davis
Directeur général
US$15.5m
Rémunération totale
| Pourcentage du salaire du PDG | 8.07% |
| Durée du mandat du directeur général | 3.5yrs |
| Propriété du PDG | 0.1% |
| Durée moyenne d'occupation des postes de direction | 3.8yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 6.2yrs |
Mises à jour récentes de la gestion
Recent updates
Quest Diagnostics: Good Q1, Solid Business, Steady Share Price Upside Likely
Apr 24
DGX: Organic Guidance And Capital Returns Will Sustain Safe Haven Appeal
Analyst price targets for Quest Diagnostics have been adjusted slightly lower to $218.19 from $218.50, as analysts factor in updated views on revenue growth, profit margins, and long term P/E assumptions following a series of recent target changes across the coverage universe. Analyst Commentary Recent research updates point to a mixed but generally constructive stance on Quest Diagnostics, with multiple target changes and one fresh list inclusion helping to frame how analysts are thinking about valuation, execution, and growth risk.DGX: Organic Guidance And Capital Returns Will Support Safe Haven Profile
Analysts have raised their price targets on Quest Diagnostics by between $5 and $30, largely pointing to recently issued organic revenue growth guidance and viewing the broader diagnostic lab space as a relative safe haven within healthcare services. Analyst Commentary Recent Street research around Quest Diagnostics and its closest peer highlights a constructive setup for the broader diagnostic lab group, with price target moves on Quest generally framed against views that the sector can act as a relative safe haven within healthcare services.DGX: Premium Multiple And Capital Returns Look Supported By Organic Revenue Guidance
Analysts have raised their price targets on Quest Diagnostics by a range of $5 to $30, citing the company’s recent organic revenue growth guidance and viewing the diagnostic testing space as a relative safe haven within healthcare services. Analyst Commentary Recent research on Quest Diagnostics highlights a cluster of higher price targets and an upgrade, with many investors treating large diagnostic labs as a relatively defensive corner of healthcare services.DGX: Fair Outlook As Premium Multiple And Capital Returns Shape Future Earnings
Analysts raised their price target on Quest Diagnostics by about $1 to $218.50, reflecting refined assumptions that include slightly higher revenue growth, a similar discount rate, modestly adjusted profit margins, and a small change in future P/E expectations, supported by broadly positive recent research across the diagnostic lab space. Analyst Commentary Street research around Quest Diagnostics has focused on how the company is positioned within the broader diagnostic lab group, with recent moves in peer guidance and a series of price target changes shaping sentiment on both upside potential and execution risk.DGX: Fair Outlook As Higher Payouts And Consumer Labs Support Future Earnings
Analysts have lifted their price target on Quest Diagnostics by about $18, reflecting slightly higher modeled revenue growth and a somewhat richer future P/E assumption, even as projected profit margins are trimmed in line with recent Street research that has broadly raised targets across the lab testing group. Analyst Commentary Bullish analysts have broadly raised their price targets on Quest Diagnostics, reflecting a more constructive view on the lab testing group as a whole and on Quest's positioning within it.DGX: Fair Outlook As Consumer Lab Partnerships And Margins Support Future Earnings
Analysts have inched up their fair value estimate for Quest Diagnostics to about $199 per share, a move they tie to slightly higher margin and P/E assumptions following recent research that points to potential upside to current earnings estimates. Analyst Commentary Recent Street research points to potential upside to current earnings estimates for Quest Diagnostics, which is feeding into a more constructive view on the stock’s valuation and execution risk.DGX: Future Consumer Lab Partnerships And Neurology Tests Will Support Balanced Outlook
Analysts have inched up their price target on Quest Diagnostics to about $198.38 from roughly $198.06, reflecting refreshed assumptions around slightly higher revenue growth, a small adjustment to profit margins, and a near steady forward P/E outlook. What's in the News Hims & Hers Health is offering lab testing that it views as a potential US$1b business, with customers accessing testing through Quest Diagnostics and then receiving results and care plans through the Hims platform (Wall Street Journal).DGX: Future Lab Partnerships And Testing Pipeline Will Support Bullish Outlook
Analysts lifted their price target for Quest Diagnostics by about US$1 to roughly US$198, citing recent Q3 results with sales and earnings ahead of consensus; raised full year guidance; firm organic volume trends; and growing interest in longer term opportunities, such as the Haystack MRD test and a generally supportive lab testing backdrop. Analyst Commentary Street research following the Q3 report points to a generally constructive tone, with multiple firms lifting their price targets and highlighting both execution on current fundamentals and potential longer term growth drivers.DGX: Future Lab Partnerships And Testing Pipeline Will Support Balanced Outlook
Analysts have nudged their price targets on Quest Diagnostics higher by between $5 and $25 per share, citing solid Q3 outperformance, raised guidance, and confidence in organic growth and future testing catalysts. Analyst Commentary Street research following the Q3 print highlights a generally constructive stance on Quest Diagnostics, with most price target increases framed around stronger than expected fundamentals and improving visibility into growth drivers over the next two years.DGX: Future Volume Gains And Lab Partnerships Will Support Balanced Outlook
The analyst price target for Quest Diagnostics was modestly increased to $197.31 from $197.25. Analysts cited stronger-than-expected earnings, raised guidance, and continued positive core trends as the rationale for the update.DGX: Future Revenue Expansion And Partnerships Will Balance Near-Term Risks
Quest Diagnostics saw its analyst price target increase, with several firms now projecting new targets between $195 and $215 per share. Analysts cite strong quarterly results and ongoing positive momentum in core business trends.DGX: Core Volume Momentum And New Blood Tests Will Drive Share Momentum
Quest Diagnostics' analyst fair value estimate has been raised from $191.56 to $197.25 per share. This change reflects analysts' upbeat outlook after strong quarterly results, improved profit margins, and continued momentum in core business trends.Preventive Diagnostics And Automation Will Shape Future Healthcare
Analysts have raised their fair value estimate for Quest Diagnostics from $188.19 to $191.56 per share, citing ongoing stable end markets and improving revenue growth expectations. Analyst Commentary Recent street research has highlighted a mix of optimism and caution surrounding Quest Diagnostics.Earnings Not Telling The Story For Quest Diagnostics Incorporated (NYSE:DGX)
Aug 20
Return Trends At Quest Diagnostics (NYSE:DGX) Aren't Appealing
Jun 21Is Quest Diagnostics Incorporated (NYSE:DGX) Trading At A 48% Discount?
May 11Quest Diagnostics: Good Growth Prospects, But Little To No Upside Left At Current Valuation
Jan 28Quest Diagnostics: Organic Growth Leads To Q3 Earnings Beat
Oct 24Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$1b |
| Dec 31 2025 | US$15m | US$1m | US$988m |
| Sep 30 2025 | n/a | n/a | US$963m |
| Jun 30 2025 | n/a | n/a | US$945m |
| Mar 31 2025 | n/a | n/a | US$892m |
| Dec 31 2024 | US$14m | US$1m | US$866m |
| Sep 30 2024 | n/a | n/a | US$838m |
| Jun 30 2024 | n/a | n/a | US$836m |
| Mar 31 2024 | n/a | n/a | US$842m |
| Dec 31 2023 | US$13m | US$1m | US$850m |
| Sep 30 2023 | n/a | n/a | US$759m |
| Jun 30 2023 | n/a | n/a | US$790m |
| Mar 31 2023 | n/a | n/a | US$789m |
| Dec 31 2022 | US$12m | US$806k | US$942m |
| Sep 30 2022 | n/a | n/a | US$1b |
| Jun 30 2022 | n/a | n/a | US$1b |
| Mar 31 2022 | n/a | n/a | US$2b |
| Dec 31 2021 | US$4m | US$625k | US$2b |
| Sep 30 2021 | n/a | n/a | US$2b |
| Jun 30 2021 | n/a | n/a | US$2b |
| Mar 31 2021 | n/a | n/a | US$2b |
| Dec 31 2020 | US$4m | US$577k | US$1b |
| Sep 30 2020 | n/a | n/a | US$1b |
| Jun 30 2020 | n/a | n/a | US$749m |
| Mar 31 2020 | n/a | n/a | US$771m |
| Dec 31 2019 | US$3m | US$590k | US$835m |
Rémunération vs marché: La rémunération totale de Jim ($USD 15.50M ) est dans la moyenne des entreprises de taille similaire sur le marché US ($USD 14.60M ).
Rémunération et revenus: La rémunération de Jim a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.
PDG
Jim Davis (62 yo)
Mr. James E. Davis, also known as Jim, serves as Chief Executive Officer and President at Quest Diagnostics Incorporated since November 1, 2022 and serves as its Director since November 2022 and Chairman o...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Chairman | 3.5yrs | US$15.50m | 0.13% $ 27.4m | |
| Executive VP & CFO | 3.8yrs | US$4.43m | 0.030% $ 6.4m | |
| Senior VP & General Counsel | 26.8yrs | US$2.56m | 0.039% $ 8.3m | |
| Executive Vice President of Regional Businesses | no data | US$3.56m | 0.065% $ 13.8m | |
| Senior Vice President of Clinical Solutions | 3.8yrs | US$2.58m | 0.014% $ 3.0m | |
| Senior VP | 7.1yrs | pas de données | 0.032% $ 6.9m | |
| Senior VP and Chief Information & Digital Officer | 2yrs | pas de données | pas de données | |
| Interim VP of Investor Relations & VP Finance | less than a year | pas de données | pas de données | |
| Senior VP & Chief Compliance Officer | 3.6yrs | pas de données | pas de données | |
| Senior VP and Chief Marketing & Communications Officer | no data | pas de données | pas de données | |
| Senior VP & Chief Human Resources Officer | 8.3yrs | pas de données | pas de données | |
| Senior Vice President of Diagnostic Services | 4.1yrs | US$2.15m | 0.014% $ 2.9m |
Gestion expérimentée: L'équipe de direction de DGX est considérée comme expérimentée (ancienneté moyenne 3.8 ans).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Chairman | 3.5yrs | US$15.50m | 0.13% $ 27.4m | |
| Independent Director | 12.3yrs | US$339.92k | 0.024% $ 5.1m | |
| Independent Director | 2yrs | US$324.92k | 0.000020% $ 4.3k | |
| Lead Independent Director | 14.4yrs | US$379.92k | pas de données | |
| Independent Director | 21.4yrs | US$349.92k | 0.027% $ 5.7m | |
| Independent Director | 7.3yrs | US$344.92k | 0.0038% $ 810.5k | |
| Director | less than a year | pas de données | pas de données | |
| Independent Director | 11.8yrs | US$344.92k | 0.016% $ 3.3m | |
| Independent Director | 6.2yrs | US$324.92k | 0.0082% $ 1.7m | |
| Independent Director | 4.8yrs | US$324.92k | pas de données | |
| Independent Director | 3yrs | US$324.92k | 0.0026% $ 550.3k |
Conseil d'administration expérimenté: Les membres du conseil d'administration de DGX sont considérés comme expérimentés (ancienneté moyenne 6.2 ans).
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/03 20:11 |
| Cours de l'action en fin de journée | 2026/05/01 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Quest Diagnostics Incorporated est couverte par 36 analystes. 16 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Eric Coldwell | Baird |
| Luke Sergott | Barclays |